Cancer Treatment Reviews

Papers
(The H4-Index of Cancer Treatment Reviews is 45. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Editorial Board262
Comparison of the pathological complete response between immunohistochemistry HER2 (3 + ) and HER2 (2 + )/ISH + Early-stage breast cancer: a systematic review and meta-analysis198
Transformation from EGFR-mutant lung adenocarcinoma to small-cell lung cancer: from clonal evolution to lineage reprogramming177
Current indications and future perspectives for antibody-drug conjugates in brain metastases of breast cancer161
Interleukin-8: a tumor-agnostic biomarker integrating cancer biology and host response across solid tumors141
Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review124
Adjuvant CDK4/6 inhibitors in breast cancer: Interpreting trial design, evidence, and uncertainty116
The interplay of clonal hematopoiesis and cancer: Clinical implications in oncology95
Therapeutic advances in Tenosynovial giant cell Tumor: Targeting the CSF1/CSF1R axis94
Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer93
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer93
A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC)81
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint in80
Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials77
Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives75
Proton therapy in breast cancer: bridging medical and radiation oncology75
Surgical tumor volume reduction in patients with brain metastases: A systematic review and meta-analysis68
Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches68
Editorial Board61
FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma59
Opportunities and challenges for non–small cell lung cancer brain metastases in the immunotherapy era58
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?57
Emerging mechanisms of triple-negative breast cancer radioresistance: Interplay between cancer cell mechanisms and the tumor immune microenvironment55
If it’s a target, it’s a pan-cancer target: Tissue is not the issue55
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev.54
Emerging antibody-based therapies for the treatment of acute myeloid leukemia54
Revisiting patient preference in resectable and irradiable stage III NSCLC in the immunotherapy era53
Optimizing care in early phase cancer trials: The role of palliative care53
Advancements in liquid biopsy for breast Cancer: Molecular biomarkers and clinical applications53
De-escalation strategies with targeted therapies in non-small cell lung cancer51
Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials51
Havoc in harmony: Unravelling the intricacies of angiogenesis orchestrated by the tumor microenvironment51
Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC51
Editorial Board50
Uncertainties and controversies in axillary management of patients with breast cancer50
Editorial Board50
Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes49
Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer: What have we accomplished so far?48
Circulating tumor DNA in breast cancer: From technological foundation to clinical implementation48
Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck47
A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?47
CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation47
Combining antibody-drug conjugates with immune checkpoint inhibitors: A new paradigm for breast cancer therapy47
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations46
Managing strategies of chemotherapy and radiotherapy-induced oral mucositis46
0.084003925323486